Pretreatment patient characteristics
| . | Ofatumumab 500 mg (n = 31) . | Ofatumumab 1000 mg (n = 30) . |
|---|---|---|
| Characteristic, median (range) | ||
| Age, y | 56 (38-73) | 56 (38-72) |
| β-2M, mg/L | 4 (1.8-11.5) | 4 (2.1-10.7) |
| Lactate dehydrogenase, IU/L | 216 (125-566) | 234 (147-1144) |
| Thymidine kinase, IU/L | 23 (5-171) | 32 (5-201) |
| Lymphocytes, ×109/L | 93 (4-302) | 77 (8-307) |
| Neutrophils, ×109/L | 5 (1.4-13.9) | 4.4 (0.9-13.4) |
| Hemoglobin, g/dL | 12 (8.0-14.9) | 12.3 (6.6-15.8) |
| Platelets, ×109/L | 168 (58-351) | 135 (50-318) |
| Characteristic, no. of patients (%) | ||
| Rai stage III-IV | 12 (39) | 16 (53) |
| Binet stage C | 8 (26) | 12 (40) |
| β-2M > 3.5 mg/L | 19 (61) | 20 (67) |
| ECOG performance status 1-2 | 15 (48) | 12 (40) |
| Palpable lymph nodes > 5 cm | 5 (16) | 5 (17) |
| CD38-positive (≥ 30%) | 8 (26) | 4 (13) |
| Unmutated IGHV* | 16 (52) | 9 (30) |
| FISH genomic abnormality† | ||
| 17p del | 2 (6) | 6 (20) |
| 11q del | 7 (23) | 3 (10) |
| Trisomy 12 | 4 (13) | 5 (17) |
| No abnormality | 5 (16) | 2 (7) |
| 13q del (sole) | 12 (39) | 13 (43) |
| O-FC courses received, no. | ||
| 6 | 22 (71) | 17 (57) |
| 4-5 | 2 (6) | 7‡ (23) |
| 1-3 | 7 (23) | 6 (20) |
| . | Ofatumumab 500 mg (n = 31) . | Ofatumumab 1000 mg (n = 30) . |
|---|---|---|
| Characteristic, median (range) | ||
| Age, y | 56 (38-73) | 56 (38-72) |
| β-2M, mg/L | 4 (1.8-11.5) | 4 (2.1-10.7) |
| Lactate dehydrogenase, IU/L | 216 (125-566) | 234 (147-1144) |
| Thymidine kinase, IU/L | 23 (5-171) | 32 (5-201) |
| Lymphocytes, ×109/L | 93 (4-302) | 77 (8-307) |
| Neutrophils, ×109/L | 5 (1.4-13.9) | 4.4 (0.9-13.4) |
| Hemoglobin, g/dL | 12 (8.0-14.9) | 12.3 (6.6-15.8) |
| Platelets, ×109/L | 168 (58-351) | 135 (50-318) |
| Characteristic, no. of patients (%) | ||
| Rai stage III-IV | 12 (39) | 16 (53) |
| Binet stage C | 8 (26) | 12 (40) |
| β-2M > 3.5 mg/L | 19 (61) | 20 (67) |
| ECOG performance status 1-2 | 15 (48) | 12 (40) |
| Palpable lymph nodes > 5 cm | 5 (16) | 5 (17) |
| CD38-positive (≥ 30%) | 8 (26) | 4 (13) |
| Unmutated IGHV* | 16 (52) | 9 (30) |
| FISH genomic abnormality† | ||
| 17p del | 2 (6) | 6 (20) |
| 11q del | 7 (23) | 3 (10) |
| Trisomy 12 | 4 (13) | 5 (17) |
| No abnormality | 5 (16) | 2 (7) |
| 13q del (sole) | 12 (39) | 13 (43) |
| O-FC courses received, no. | ||
| 6 | 22 (71) | 17 (57) |
| 4-5 | 2 (6) | 7‡ (23) |
| 1-3 | 7 (23) | 6 (20) |